Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity

Retina

Volumn 34, Issue 5, 2014, Pages 853-859

  Ozkaya, Abdullah ^a   Alkin, Zeynep ^a   Yazici, Ahmet T ^a   Demirok, Ahmet ^b  

^a Beyoglu Eye Training and Research Hospital   (Turkey)

^b Medeniyet University   (Turkey)

Author keywords

Age related macular degeneration; Cataract; Lens; Pseudophakia; Ranibizumab; Visual acuity

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTERVENTION STUDY; LENS DISEASE; MAJOR CLINICAL STUDY; MALE; PHAKIA; PSEUDOPHAKIA; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; LENS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; TREATMENT OUTCOME; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTERVENTION STUDIES; INTRAVITREAL INJECTIONS; LENS, CRYSTALLINE; MALE; MIDDLE AGED; PSEUDOPHAKIA; RETINA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84899969708     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000024     Document Type: Article

References (34)

1. Soubrane G, Coscas G, Français C, Koenig F. Occult subretinal new vessels in age-related macular degeneration. Natural history and early laser treatment. Ophthalmology 1990;97: 649-657.
2. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642.
3. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220-1231.
4. Singerman LJ, Kalski RS. Tunable dye laser photocoagulation for choroidal neovascularization complicating age-related macular degeneration. Retina 1989;9:247-257.
5. Akduman L, Karavellas MP, MacDonald JC, et al. Macular translocation with retinotomy and retinal rotation for exudative age-related macular degeneration. Retina 1999;19:418-423.
6. Tornambe PE, Poliner LS, Hovey LJ, Taren D. Scatter macular photocoagulation for subfoveal neovascular membranes in agerelated macular degeneration. A pilot study. Retina 1992;12: 305-314.
7. Connor TB Jr, Wolf MD, Arrindell EL, Mieler WF. Surgical removal of an extrafoveal fibrotic choroidal neovascular membrane with foveal serous detachment in age-related macular degeneration. Retina 1994;14:125-129.
8. Rubin GS, Bressler NM; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast on sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation-TAP report No 4. Retina 2002;22:536-544.
9. Margherio RR, Margherio AR, DeSantis ME. Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina 2000;20:325-330.
10. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-390.
11. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1432-1444.
12. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
13. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
14. Schmidt-Erfurth U, Eldem B, Guymer R, et al; EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118: 831-839.
15. Martin DF, Maguire MG, Ying GS, et al; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011:364; 1897-1908.
16. Takahashi M, Sato T, Kishi S. Intravitreal bevacizumab for age-related macular degeneration with good visual acuity. Jpn J Ophthalmol 2010;54:565-570.
17. Axer-Siegel R, Bor E, Bourla DH, et al. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity. Retina 2012;32:1811-1820.
18. Saito M, Lida T, Kano M. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Retina 2012;32:1250-1259.
19. Baba T, Kitahashi M, Kubota-Taniai M, et al. Two-year course of subfoveal pigment epithelial detachment in eyes with agerelated macular degeneration and visual acuity better than 20/40. Ophthalmologica 2012;228:102-109.
20. Monés J, Biarnés M, Trindade F, Casaroli-Marano R. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity. Graefes Arch Clin Exp Ophthalmol 2012;250: 1737-1744.
21. Raja MS, Saldana M, Goldsmith C, Burton BJ. Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes. Br J Ophthalmol 2010;94:1543-1545.
22. Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macular degeneration in eyes with baseline visual acuity better than 6/12. Eye (Lond) 2011;25: 1617-1621.
23. Weinberg DV, Shapiro H, Ehrlich JS. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology 2013; 12:1278-1282.
24. Baek JS, Cho HJ, Cho SW, et al. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes. Retina 2013;33:467-473.
25. Algvere PV, Marshall J, Seregard S. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand 2006;84:4-15.
26. Hafezi F, Marti A, Munz K, Remé CE. Light-induced apoptosis: differential timing in the retina and pigment epithelium. Exp Eye Res 1997;64:963-970.
27. Grimm C, Reme CE, Rol PO, Williams TP. Blue light's effects on rhodopsin: photoreversal of bleaching in living rat eyes. Invest Ophthalmol Vis Sci 2000;41:3984-3990.
28. Pollack A, Marcovich A, Bukelman A, Oliver M. Age-related macular degeneration after extracapsular cataract extraction with intraocular lens implantation. Ophthalmology 1996;103: 1546-1554.
29. Klein R, Klein BE, Jensen SC, Cruickshanks KJ. The relationship of ocular factors to the incidence and progression of agerelated maculopathy. Arch Ophthalmol 1998;116:506-513.
30. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology 2002;109:1092-1097.
31. Wang JJ, Klein R, Smith W, et al. Cataract surgery and the 5-year incidence of late-stage age-related maculopathy: pooled findings from the Beaver Dam and Blue Mountains eye studies. Ophthalmology 2003;110:1960-1967.
32. van der Schaft TL, Mooy CM, de Bruijn WC, et al. Increased prevalence of disciform macular degeneration after cataract extraction with implantation of an intraocular lens. Br J Ophthalmol 1994;78:441-445.
33. Smith BT, Belani S, Ho AC. Light energy, cataract surgery, and progression of age-related macular degeneration. Curr Opin Ophthalmol 2005;16:166-169.
34. Wang JJ, Fong CS, Rochtchina E, et al. Risk of age-related macular degeneration 3 years after cataract surgery: paired eye comparisons. Ophthalmology 2012;119:2298-2303.